1887
Volume 2014, Issue 4
  • ISSN: 2305-7823
  • E-ISSN:

There is no abstract available for this article.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2014.49
2015-03-01
2019-10-15
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2014/4/gcsp.2014.49.html?itemId=/content/journals/10.5339/gcsp.2014.49&mimeType=html&fmt=ahah

References

  1. [1]. Baigent   C., , Blackwell   L., , Emberson   J., , Holland   LE., , Reith   C., , Bhala   N., , Peto   R., , Barnes   EH., , Keech   A., , Simes   J., , Collins   R. . Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. . Lancet . 2010; ;376: 9753 : 1670– 1681 .
    [Google Scholar]
  2. [2]. Stone   NJ., , Robinson   JG., , Lichtenstein   AH., , Merz   CNB., , Blum   CB., , Eckel   RH., , Goldberg   AC., , Gordon   D., , Levy   D., , Lloyd-Jones   DM., , McBride   P., , Schwartz   JS., , Shero   ST., , Smith   SC., , Watson   K., , Wilson   PWF. . 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. . J. Am. Coll. Cardiol.   2014; ;63: 25_PA : 2889– 2934 .
    [Google Scholar]
  3. [3]. Reiner   Z., , Catapano   AL., , De Backer   G., , Graham   I., , Taskinen   MR., , Wiklund   O., , Agewall   S., , Alegria   E., , Chapman   MJ., , Durrington   P., , Erdine   S., , Halcox   J., , Hobbs   R., , Kjekshus   J., , Filardi   PP., , Riccardi   G., , Storey   RF., , Wood   D. . ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). . Eur. Heart J.   2011; ;32: : 1769– 1818 .
    [Google Scholar]
  4. [4]. Anderson   TJ., , Grégoire   J., , Hegele   RA., , Couture   P., , Mancini   GB., , McPherson   R., , Francis   GA., , Poirier   P., , Lau   DC., , Grover   S., , Genest   J Jr., , Carpentier   AC., , Dufour   R., , Gupta   M., , Ward   R., , Leiter   LA., , Lonn   E., , Ng   DS., , Pearson   GJ., , Yates   GM., , Stone   JA., , Ur   E. . 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. . Can. J. Cardiol.   2013; ;29: : 151– 167 .
    [Google Scholar]
  5. [5]. Zhang   H., , Plutzky   J., , Skentzos   S., , Morrison   F., , Mar   P., , Shubina   M., , Turchin   A. . Discontinuation of statins in routine care settings: a cohort study. . Ann. Intern. Med.   2013; ;158: 7 : 526– 534 .
    [Google Scholar]
  6. [6]. Lambert   G., , Sjouke   B., , Choque   B., , Kastelein   JJP., , Hovingh   GK. . The PCSK9 decade. . J. Lipid Res.   2012; ;53: 12 : 2515– 2524 .
    [Google Scholar]
  7. [7]. Elguindy   A., , Yacoub   MH. . The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research. . Glob. Cardiol. Sci. Pract.   2013; ;4: : 1– 5 .
    [Google Scholar]
  8. [8]. Piper   DE., , Jackson   S., , Liu   Q., , Romanow   WG., , Shetterly   S., , Thibault   ST., , Shan   B., , Walker   NP. . Article The Crystal Structure of PCSK9: A Regulator of Plasma LDL-Cholesterol. . Structure . 2007; ;15: : 545– 552 .
    [Google Scholar]
  9. [9]. Giugliano   RP., , Desai   NR., , Kohli   P., , Rogers   WJ., , Somaratne   R., , Huang   F., , Liu   T., , Mohanavelu   S., , Hoffman   EB., , McDonald   ST., , Abrahamsen   TE., , Wasserman   SM., , Scott   R., , Sabatine   MS. . Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type9 incombination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI57): a randomised, placebo-controlled, dose- ranging, phase2 study. . Lancet . 2012; ;380: : 2007– 2017 .
    [Google Scholar]
  10. [10]. Raal   F., , Scott   R., , Somaratne   R., , Bridges   I., , Li   G., , Wasserman   SM., , Stein   EA. . Low-density lipoprotein cholesterol- lowering effects of AMG145, a monoclonal antibody to proprotein convertase subtilisin/ kexin type9 serine protease in patients with heterozygous familial hypercholesterolemia: theReduction of LDL-C with PCSK9 Inhibi. . Circulation . 2012; ;126: : 2408– 2417 .
    [Google Scholar]
  11. [11]. Sullivan   D., , Olsson   AG., , Scott   R., , Kim   JB., , Xue   A., , Gebski   V., , Wasserman   SM., , Stein   EA. . Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. . JAMA . 2012; ;308: : 2497– 2506 .
    [Google Scholar]
  12. [12]. Koren   MJ., , Giugliano   RP., , Raal   FJ., , Sullivan   D., , Bolognese   M., , Langslet   G., , Civeira   F., , Somaratne   R., , Nelson   P., , Liu   T., , Scott   R., , Wasserman   SM., , Sabatine   MS. . Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial. . Circulation . 2013; ;129: 2 : 234– 243 .
    [Google Scholar]
  13. [13]. Urban   D., , Pöss   J., , Böhm   M., , Laufs   U. . Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. . J. Am. Coll. Cardiol.   2013; ;62: 16 : 1401– 1408 .
    [Google Scholar]
  14. [14]. Stroes   E., , Colquhoun   D., , Sullivan   D., , Civeira   F., , Rosenson   RS., , Watts   GF., , Bruckert   E., , Cho   L., , Dent   R., , Knusel   B., , Xue   A., , Scott   R., , Wasserman   SM., , Rocco   M. . Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance. . J Am Coll Cardiol . 2014; ;63: 23 : 2541– 2548 .
    [Google Scholar]
  15. [15]. Raal   FJ., , Stein   EA., , Dufour   R., , Turner   T., , Civeira   F., , Burgess   L., , Langslet   G., , Scott   R., , Olsson   AG., , Sullivan   D., , Hovingh   GK., , Cariou   B., , Gouni-Berthold   I., , Somaratne   R., , Bridges   I., , Scott   R., , Wasserman   SM., , Gaudet   D. . PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. . Lancet . 2014; ; , October. doi:10.1016/S0140-6736(14)61399-4 .
    [Google Scholar]
  16. [16]. Raal   FJ., , Honarpour   N., , Blom   DJ., , Hovingh   GK., , Xu   F., , Scott   R., , Wasserman   SM., , Stein   EA. . Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. . Lancet . 2014; ;   October. doi:10.1016/S0140-6736(14)61374-X .
    [Google Scholar]
  17. [17]. Robinson   JG., , Nedergaard   BS., , Rogers   WJ., , Fialkow   J., , Neutel   JM., , Ramstad   D., , Somaratne   R., , Legg   JC., , Nelson   P., , Scott   R., , Wasserman   SM., , Weiss   R. . Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial. . JAMA . 2014; ;311: 18 : 1870– 1882 .
    [Google Scholar]
  18. [18]. Blom   DJ., , Hala   T., , Bolognese   M., , Lillestol   MJ., , Toth   PD., , Burgess   L., , Ceska   R., , Roth   E., , Koren   MJ., , Ballantyne   CM., , Monsalvo   ML., , Tsirtsonis   K., , Kim   JB., , Scott   R., , Wasserman   SM., , Stein   EA. . A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. . NEJM . 2014; ;370: 19 : 1809– 1819 .
    [Google Scholar]
  19. [19]. Dadu   RT., , Ballantyne   CM. . Lipid lowering with PCSK9 inhibitors. . Nat. Rev. Cardiol.   2014; ;11: 10 : 563– 575 .
    [Google Scholar]
  20. [20]. Larosa   JC., , Pedersen   TR., , Somaratne   R., , Wasserman   SM. . Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events. . Am. J. Cardiol.   2013; ;111: : 1221– 1229 .
    [Google Scholar]
  21. [21]. Martin   SS., , Blaha   MJ., , Elshazly   MB., , Brinton   EA., , Toth   PP., , McEvoy   JW., , Joshi   PH., , Kulkarni   KR., , Mize   PD., , Kwiterovich   PO., , DeFilippis   AP., , Blumenthal   RS., , Jones   SR. . Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. . J. Am. Coll. Cardiol.   2013; ;62: : 732– 739 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2014.49
Loading
/content/journals/10.5339/gcsp.2014.49
Loading

Data & Media loading...

  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error